News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
57 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (2)
3 (145)
4 (188)
5 (190)
6 (124)
7 (71)
10 (179)
11 (91)
12 (168)
13 (122)
14 (57)
17 (142)
18 (120)
19 (151)
20 (179)
21 (55)
24 (93)
25 (131)
26 (123)
27 (118)
28 (134)
31 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
7
10
11
12
13
14
17
18
19
20
21
24
25
26
27
28
31
Business
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect shareholders against Tang Capital’s growing stake in the company.
March 14, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review
Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate luveltamab tazevibulin, which it was studying for ovarian cancer. The biotech will seek licensing opportunities for the asset.
March 14, 2025
·
3 min read
·
Tristan Manalac
GLP-1
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related conditions.
March 14, 2025
·
1 min read
·
Dan Samorodnitsky
Government
FDA Makes Flu Vaccine Recommendations Without Convening Advisors
The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.
March 14, 2025
·
2 min read
·
Tristan Manalac
Pipeline
Pfizer’s Pipeline Pruning Ends Early-Stage STING Trial
Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
March 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid
March 14, 2025
·
20 min read
Press Releases
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
March 14, 2025
·
53 min read
Press Releases
ProQR Announces Year End 2024 Operating and Financial Results
March 14, 2025
·
9 min read
Press Releases
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
March 14, 2025
·
6 min read
Press Releases
Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board
March 14, 2025
·
4 min read
1 of 6
Next
